Clinical Commissioning Policy: Addition of rituximab to first-line standard chemotherapy for CD20 positive B-cell precursor acute lymphoblastic leukaemia (Adults)

Document first published:
Page updated:
Topic:
Publication type:

The addition of rituximab to first-line standard chemotherapy is recommended to be available as a treatment option through routine commissioning for CD20 positive B-cell precursor acute lymphoblastic leukaemia within the criteria set out in this document.

Document

Clinical Commissioning Policy: Addition of rituximab to first-line standard chemotherapy for CD20 positive B-cell precursor acute lymphoblastic leukaemia (Adults)

Clinical Commissioning Policy: Addition of rituximab to first-line standard chemotherapy for CD20 positive B-cell precursor acute lymphoblastic leukaemia (Adults)

  • PDF
  • 111 KB
  • 9 pages

Document

Evidence review: Addition of rituximab to first-line standard chemotherapy for CD20 positive B-cell precursor acute lymphoblastic leukaemia (Adults)

Evidence review: Addition of rituximab to first-line standard chemotherapy for CD20 positive B-cell precursor acute lymphoblastic leukaemia (Adults)

  • PDF
  • 543 KB
  • 26 pages

Document

Engagement report: Addition of rituximab to first-line standard chemotherapy for CD20 positive B-cell precursor acute lymphoblastic leukaemia (Adults)

Engagement report: Addition of rituximab to first-line standard chemotherapy for CD20 positive B-cell precursor acute lymphoblastic leukaemia (Adults)

  • PDF
  • 107 KB
  • 3 pages

Document

Consultation report: Addition of rituximab to first-line standard chemotherapy for CD20 positive B-cell precursor acute lymphoblastic leukaemia (Adults)

Consultation report: Addition of rituximab to first-line standard chemotherapy for CD20 positive B-cell precursor acute lymphoblastic leukaemia (Adults)

  • PDF
  • 89 KB
  • 3 pages

Document

CPAG summary report: Addition of rituximab to first-line standard chemotherapy for CD20 positive B-cell precursor acute lymphoblastic leukaemia (Adults)

CPAG summary report: Addition of rituximab to first-line standard chemotherapy for CD20 positive B-cell precursor acute lymphoblastic leukaemia (Adults)

  • PDF
  • 164 KB
  • 8 pages

Document

Equality and Health Inequalities Impact Assessment (EHIA): Addition of rituximab to first-line standard chemotherapy for CD20 positive B-cell precursor acute lymphoblastic leukaemia (Adults)

Equality and Health Inequalities Impact Assessment (EHIA): Addition of rituximab to first-line standard chemotherapy for CD20 positive B-cell precursor acute lymphoblastic leukaemia (Adults)

  • PDF
  • 143 KB
  • 12 pages

Document

Clinical panel report: Addition of rituximab to first-line standard chemotherapy for CD20 positive B-cell precursor acute lymphoblastic leukaemia (Adults) - April 2020

Clinical panel report: Addition of rituximab to first-line standard chemotherapy for CD20 positive B-cell precursor acute lymphoblastic leukaemia (Adults) - April 2020

  • PDF
  • 76 KB
  • 2 pages

Document

Clinical panel report: Addition of rituximab to first-line standard chemotherapy for CD20 positive B-cell precursor acute lymphoblastic leukaemia (Adults) - November 2018

Clinical panel report: Addition of rituximab to first-line standard chemotherapy for CD20 positive B-cell precursor acute lymphoblastic leukaemia (Adults) - November 2018

  • PDF
  • 31 KB
  • 2 pages

Document

Clinical panel report: Addition of rituximab to first-line standard chemotherapy for CD20 positive B-cell precursor acute lymphoblastic leukaemia (Adults) - July 2018

Clinical panel report: Addition of rituximab to first-line standard chemotherapy for CD20 positive B-cell precursor acute lymphoblastic leukaemia (Adults) - July 2018

  • PDF
  • 81 KB
  • 2 pages